Stay updated on Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial
Sign up to get notified when there's something new on the Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial page.

Latest updates to the Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial page
- Check3 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedPage revision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check39 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check68 days agoChange DetectedThe page revision label was updated from v3.4.1 to v3.4.2. No substantive changes to study details are indicated.SummaryDifference0.0%

- Check75 days agoChange DetectedThe page now shows Revision: v3.4.1 and the previous Revision: v3.4.0 was removed, which appears to be a minor metadata update with no changes to study content or availability. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check83 days agoChange DetectedThe page now shows a glossary and includes updated metadata (Last Update Submitted that Met QC Criteria) and Revision: v3.4.0. The previous QC wording, older FEAR Act wording, and the prior revision (v3.3.4) have been removed.SummaryDifference0.1%

Stay in the know with updates to Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial page.